Reports
Sale
Global Autologous Cell Therapy Market Size, Trends, Report: By Therapy: Autologous Stem Cell Therapy, Autologous Cellular Immunotherapies; By Source: Bone Marrow, Epidermis, Others; By Application: Oncology, Musculoskeletal Disorder, Blood Disorder, Others; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Global Autologous Cell Therapy Market Outlook
The autologous cell therapy market size was valued at USD 7.8 billion in 2023, driven by the emphasis on precision medicine to treat chronic diseases across the globe. The market is expected to grow at a CAGR of 19.4% during the forecast period of 2024-2032, with the values likely to rise from USD 9.3 billion in 2024 to USD 38.4 billion by 2032.
Autologous Cell Therapy: Introduction
Autologous cell therapy is a technique that uses an individual’s own cells or tissues to be processed and expanded outside the body and later reintroduced into the donor. This therapy provides advantages like biocompatibility, lower risk from systemic immunological reactions and disease transmission related to external grafts or cells.
Autologous cell therapy finds its application in dermatology, oncology, musculoskeletal as well as autoimmune disorders. It is used in treating burns and pressure ulcers, helping wound healing, expediate postoperative healing and stabilize chronic inflammation as well.
Global Autologous Cell Therapy Market Analysis
Autologous cell therapies find their applications across several domains. It is associated with less adverse side effects that may persist due to foreign materials and incompatibility between host and outside cells. With the increasing emphasis on precision medicine, patients are showing their preference towards autologous cell therapies, which has led to significant market demand.
Then autologous cell therapy market value is used effectively in wound healing. Starting in the 1980s, bioengineered skin equivalents have been effective for wound healing outcomes. However, issues like scarring, skin contracture and poor epithelialization persisted in conventional methods. Hence, researchers have been working to develop an improved and efficient method to address the side effects. In July 2023, researchers reviewed the effectiveness of an autologous cell therapy called EB-101 to treat dystrophic epidermis bullosa (RDEB) in patients. It was revealed that 81% of the wounds treated with EB-101 resulted in pain severity and healed effectively.
Around 3-5% of the world’s population is affected by autoimmune diseases. Over the years, autologous cell therapies have been widely used in the treatment of autoimmune diseases. Currently, the treatment market is observing several technical innovations. In August 2023, Artiva Biotherapeutics announced that their new investigational drug got its FDA clearance to be used in the market. AlloNK® (also known as AB-101), comes in combination with rituximab for treatment of systemic lupus erythematosus (SLE) in patients affected with active lupus nephritis (LN). Autologous CAR T-cell therapies are also used in treating selective blood cancer, predominantly B cell malignancies. Owing to its wide application, autologous cell therapy market demand is anticipated to increase in the forecast period.
Global Autologous Cell Therapy Market Segmentation
Market Breakup by Therapy
- Autologous Stem Cell Therapy
- Autologous Cellular Immunotherapies
Market Breakup by Source
- Bone Marrow
- Epidermis
- Others
Market Breakup by Application
- Oncology
- Musculoskeletal Disorder
- Blood Disorder
- Autoimmune Disease
- Others
Market Breakup by End User
- Hospitals
- Research Centres
- Cancer Treatment Centres
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Autologous Cell Therapy Market Overview
The global market for autologous cell therapy is constantly growing and witnessing significant attention as a potential treatment for many diseases. The active participation of various healthcare pioneers expediating research and development in the field. For instance, in June 2023, AstraZeneca announced an agreement with Quell Therapeutics to treat type 1 diabetes and inflammatory bowel disease with the help of developing autologous multi-modular Treg cell therapy.
The United States is expected to lead the market with latest investments in the infrastructure for better research and development. Bristol Myers Squibb got its FDA clearance to set up a commercial production for the company’s latest cell therapy manufacturing facility in Devens, Massachusetts. Therefore, United States will hold a huge portion of the autologous cell therapy market share in the forecast period. However, considering the technological and academic growth in the Asia Pacific, the region is anticipated to witness the fastest growth in upcoming years.
Global Autologous Cell Therapy Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Sanpower Group (Dendreon Pharmaceuticals LLC.)
- Holostem Terapie Avanzate S.r.l.
- Novartis AG
- Tego Science
- GC Biopharma (GC Cell)
- Gilead Sciences
- Johnson & Johnson (Janssen Biotech, Inc)
- Bristol Myers Squibb
- CORESTEM, Inc
- Vericel Corporation
- Opexa Therapeutics
- Lineage Cell Therapeutics, Inc.
- Pharmicell Co., Inc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Therapy |
|
| Breakup by Source |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Autologous Cell Therapy Market Overview
3.1 Global Autologous Cell Therapy Market Historical Value (2017-2023)
3.2 Global Autologous Cell Therapy Market Forecast Value (2024-2032)
4 Global Autologous Cell Therapy Market Landscape
4.1 Global Autologous Cell Therapy Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Autologous Cell Therapy Product Landscape
4.2.1 Analysis by Therapy
4.2.2 Analysis by Source
4.2.3 Analysis by Application
5 Global Autologous Cell Therapy Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Autologous Cell Therapy Market Segmentation
6.1 Global Autologous Cell Therapy Market by Therapy
6.1.1 Market Overview
6.1.2 Autologous Stem Cell Therapy
6.1.3 Autologous Cellular Immunotherapies
6.2 Global Autologous Cell Therapy Market by Source
6.2.1 Market Overview
6.2.2 Bone Marrow
6.2.3 Epidermis
6.2.4 Others
6.3 Global Autologous Cell Therapy Market by Application
6.3.1 Market Overview
6.3.2 Oncology
6.3.3 Musculoskeletal Disorder
6.3.4 Blood Disorder
6.3.5 Autoimmune Disease
6.3.6 Others
6.4 Global Autologous Cell Therapy Market by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Research Centers
6.4.4 Cancer Treatment Centres
6.4.5 Others
6.5 Global Autologous Cell Therapy Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Autologous Cell Therapy Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Autologous Cell Therapy Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Autologous Cell Therapy Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Autologous Cell Therapy Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Autologous Cell Therapy Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by Year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding & Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Supplier Landscape
18.1 Sanpower Group (Dendreon Pharmaceuticals LLC.)
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Holostem Terapie Avanzate S.r.l.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Novartis AG
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Tego Science
18.4.1 Financial Analysis
18.4.2 Financial Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 GC Biopharma (GC Cell)
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Gilead Sciences
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Johnson & Johnson (Janssen Biotech, Inc)
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Bristol Myers Squibb
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 CORESTEM, Inc
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Vericel Corporation
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 Opexa Therapeutics
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications
18.12 Lineage Cell Therapeutics, Inc.
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.12.5 Certifications
18.13 Pharmicell Co., Inc.
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.13.5 Certifications
19 Global Autologous Cell Therapy Market - Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 7.8 billion in 2023, driven by the focus on treating chronic diseases with the help of precision medicine.
The market is anticipated to grow at a CAGR of 19.4% during the forecast period of 2024-2032, likely to reach a market value of USD 38.4 billion by 2032.
Autologous cell therapies are used in offering treatment for several domains including oncology, dermatology, and autoimmune diseases. Owing to its efficacy and lesser risk of dangerous side effects, the market demand has grown.
Global healthcare industry leaders are working on expanding their research and development in the field. For instance, AstraZeneca is aiming to develop autologous multi-modular Treg cell therapies to treat type 1 diabetes and inflammatory bowel diseases with the help of developing.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.
Common application areas include oncology, musculoskeletal disorder, blood disorder, autoimmune disease, and others.
Autologous stem cell therapy and autologous cellular immunotherapies are two therapies.
Sources include bone marrow and epidermis, among others.
Major end users include hospitals, clinics, research centres, and cancer treatment centres, among others.
Key players involved in the market are Sanpower Group (Dendreon Pharmaceuticals LLC.), Holostem Terapie Avanzate S.r.l., Novartis AG, Tego Science, GC Biopharma (GC Cell), Gilead Sciences, Johnson & Johnson (Janssen Biotech, Inc), CORESTEM, Inc., Vericel Corporation, Opexa Therapeutics, Lineage Cell Therapeutics, Inc., Pharmicell Co., Inc., and Bristol Myers Squibb.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER